Formulation of filgrastim as a sterile injectable solution in vials and prefilled syringes begins with a 10 mM sodium acetate buffer adjusted to pH 4.0, 5% w/v sorbitol as tonicifier, and 0.004% w/v polysorbate 80 as surfactant. The API is dissolved to 300 µg/mL, filtered through a 0.2 µm sterilising-grade membrane, and filled aseptically under ISO 14644-1 Class 5 conditions. Polysorbate 80 is maintained at 0.004% w/v because higher surfactant loads above the critical micelle concentration can mask subvisible particle detection by light obscuration, while lower loads insufficiently protect the protein from shear at filling pumps. Silicone oil from glass barrel walls acts as a hydrophobic interface; in-process particle counts for ≥10 µm and ≥25 µm particles follow USP <787> and Ph. Eur. 2.9.19, with acceptance limits aligned to small-volume protein injections. Potency is measured by cell-proliferation assay against the WHO filgrastim reference standard; oxidised and deamidated species are resolved by reversed-phase HPLC. Endotoxin is controlled through depyrogenated primary packaging and the threshold is calculated per USP <85> from the maximum bolus dose. The finished liquid is stored at 2–8°C and protected from light; freeze-thaw cycling is excluded because ice-water interfaces generate aggregates that cannot be re-solubilised by simple dilution. Glass delamination risk in vials is evaluated by USP <1660> and container closure integrity is verified under USP <1207> and ISO 11040-4 for prefilled syringes.

When Lyophilized Cakes Require Reconstitution Below 8°C

Lyophilized filgrastim intermediates are evaluated when cold-chain integrity cannot be assured beyond 72 h at 40°C or when a dry powder format is required for subsequent solid-dosage exploratory work. The pre-lyophilization bulk typically contains filgrastim at 0.5–5.0 mg/mL, trehalose dihydrate or mannitol at 5% w/v, acetate or histidine buffer at 10–25 mM, and polysorbate 80 at 0.005–0.02% w/v. Controlled nucleation is applied at -5°C to -10°C to reduce ice crystal heterogeneity; primary drying is run at shelf temperature -25°C to -15°C and chamber pressure 0.1–0.2 mbar. Trehalose-based cakes display collapse temperatures between -28°C and -34°C, which requires conservative ramp rates of 0.5°C/min or less during freezing. Residual moisture is held below 1.5% w/w by Karl Fischer titration after secondary drying at 20–30°C for 6–12 h. Reconstitution with water for injection to 300 µg/mL produces a clear solution only when the cake remains structurally intact; collapsed or melted regions indicate localised collapse above the glass transition temperature of the amorphous phase. Subvisible particle testing after reconstitution follows USP <787> and Ph. Eur. 2.9.19. The lyophilization process is not a sterilisation step: sterilising filtration at 0.2 µm and aseptic stopper placement under grade A remain mandatory. Published data for filgrastim-specific lyophilisation cycles is limited; most cycle parameters are adapted from related 18–20 kDa recombinant protein formulations and must be confirmed by differential scanning calorimetry and freeze-drying microscopy for each biosimilar buffer composition.

For oral delayed-release capsule development, filgrastim-loaded spray-dried or lyophilised composite powders are used because the native molecule is rapidly denatured below pH 3.5 and cleaved by pepsin in the gastric compartment. Capsule contents are prepared by spray drying an aqueous feed containing filgrastim, trehalose dihydrate at 1:5 to 1:20 mass ratio, hydroxypropyl methylcellulose acetate succinate, and sodium caprate or chitosan as potential permeation enhancer; inlet temperature is kept at 90–110°C and outlet temperature below 50°C to limit thermal damage. The resulting powder is filled into size 0 or size 1 hard gelatin capsules and coated with Eudragit L 100-55 or equivalent methacrylic acid copolymer to delay release until the intestinal segment above pH 5.5. Dissolution testing uses 0.1 M HCl for 2 h followed by pH 6.8 phosphate buffer according to USP <711>; however, in vivo bioavailability remains the principal obstacle because filgrastim has a molecular mass of approximately 18.8 kDa, is highly hydrophilic, and lacks intrinsic paracellular permeability. Published data for oral filgrastim in capsule form is limited to exploratory studies; no commercial oral filgrastim capsule exists and no pharmacopoeial monograph supports this route. The operational boundary is explicit: enteric coating protects the protein from gastric inactivation but does not overcome first-pass proteolysis at the intestinal brush border or negligible transcellular absorption. Consequently, oral capsule manufacturing is confined to research-use formulation screening and early pharmacokinetic feasibility studies in animal models.

What Limits Terminal Sterilization for a Protein API?

Terminal sterilisation of filgrastim by saturated steam at 121°C for 15 min is incompatible with the 175-amino-acid sequence because heat induces irreversible unfolding, oxidation of methionine residues, and deamidation at labile asparagine-glycine sites. Bioactivity loss in phosphate-buffered solution exceeds 90% after a standard autoclave cycle, and high-molecular-weight aggregates become detectable by size-exclusion HPLC within 10 min at 100°C. Gamma irradiation at 25 kGy, a dose used for sterile medical devices, generates hydroxyl radicals that fragment the polypeptide backbone and elevate oxidised species beyond pharmacopoeial limits. Electron-beam treatment at 10–20 kGy produces similar oxidative damage in the dried state, even when the API is embedded in a glassy trehalose matrix. The only viable sterilisation approach for injectable filgrastim is aseptic processing under ISO 13408-1:2008, with 0.2 µm sterilising-grade filtration into depyrogenated containers. For oral experimental products, terminal treatment after tableting or capsule filling is similarly excluded unless process qualification demonstrates no increase in oxidised species above specification and no bioactivity loss greater than 10%. The operational boundary is that any sterilisation step after protein formulation must be considered a process risk, not a release control, unless forced degradation studies confirm stability of the folded monomer under the exact irradiation or thermal load. This constraint drives the use of aseptic granules, sterile capsules, and low-temperature drying platforms rather than conventional terminal treatments.

Oral Granule Layering Platforms for Enteric Multiparticulates

In fluid-bed top-spray processing, a filgrastim solution is sprayed onto sugar spheres of 250–355 µm diameter with hydroxypropylcellulose as binder; the inlet air temperature is maintained at 45°C or less and atomisation pressure below 1.0 bar to limit nozzle shear. The drug-layered cores are then coated with Eudragit L 30 D-55 in a Wurster column at product temperature 25–30°C, followed by talc or glycerol monostearate as anti-tacking agent. Aqueous polymer dispersions are used only when the core moisture remains below 0.5% w/w; otherwise organic coating solutions are preferred. Dissolution testing follows USP <711> delayed-release methodology with 2 h in 0.1 M HCl and subsequent pH 6.8 buffer. The bioactivity of coated granules is verified by cell-proliferation assay after dissolution to exclude denaturation at the core-coating interface. Published data for filgrastim granule layering is limited; therefore, process parameters must be validated for each binder and enteric polymer combination rather than transferred from small-molecule granulation monographs. Granule size distribution is controlled by sieve analysis per Ph. Eur. 2.9.12, with the fraction below 180 µm limited to prevent poor flow and non-uniform dissolution in exploratory oral sachet fills.

At 300 µg/mL fill concentration, prefilled syringe compatibility involves break-loose and glide force testing on 1 mL long and 1 mL short glass syringes with fluoropolymer-laminated plunger stoppers. Break-loose forces between 5 N and 15 N and glide forces below 10 N at 100 mm/min are typical targets for autoinjector platforms, but silicone oil load in the barrel must be tightly controlled because the protein adsorbs at the silicone-water interface and promotes subvisible particle formation. Silicone oil levels below 0.5 mg per syringe are achieved by baked-on or cross-linked oil processing; excess free silicone oil causes particle counts above 600 per container for ≥25 µm when combined with agitation during shipping. Syringe filling requires slow-stroke peristaltic or ceramic piston pumps to limit shear; filling needle diameter of 0.5 mm or larger is preferred. In-use stability after needle puncture is assessed by USP <790> visible particulate and USP <787> subvisible particle methods. The product is stored at 2–8°C; excursions to 25°C are limited to a cumulative 48 h in manufacturer stability protocols, and freezing is prohibited because the liquid formulation has no cryoprotectant. Container closure integrity is verified under USP <1207> and ISO 11040-4 for prefilled syringes.

Compressing Filgrastim Mini-Tablets Without Loss of Bioactivity

During direct compression of filgrastim mini-tablets for exploratory oral dose titration, excipients with high glass transition and low moisture sorption are required because the 18.8 kDa protein loses tertiary structure under mechanical shear and local heating at compaction pressures above 100 MPa. A powder blend for 2 mm mini-tablets may contain filgrastim at 0.5–2.0% w/w, trehalose dihydrate or raffinose as stabiliser, microcrystalline cellulose as diluent, crospovidone as disintegrant, and sodium stearyl fumarate as lubricant. Compression is performed on a rotary tablet press at 10–20 rpm with compaction pressure below 100 MPa; for an 8 mm flat-faced punch this corresponds to approximately 2–4 kN, while smaller 2 mm mini-tablets require proportionally lower force. Punch cooling below 30°C is applied because higher compression pressures raise tablet hardness but reduce protein bioactivity as measured by cell-proliferation assay after dissolution in pH 6.8 buffer. Tablets are coated with Eudragit L 100-55 using a pan coater at inlet air temperature 35–40°C and spray rate 2–4 g/min per 0.5 kg batch. Uniformity of dosage units is tested per USP <905>, disintegration per USP <701>, and dissolution per USP <711>. Published data for compressed filgrastim mini-tablets is limited; the compression window must be established for each biosimilar API lot because minor differences in aggregate content affect compressibility and post-compression bioactivity. No oral filgrastim tablet is approved for clinical use, and this platform is restricted to pharmaceutical research evaluating oral protein delivery with permeation enhancers or carrier systems.

Because common antimicrobial agents such as m-cresol and phenol can perturb the folded structure of 18.8 kDa proteins through hydrophobic interactions, multi-dose vial in-use stability for filgrastim is constrained. Benzyl alcohol at 0.9% w/v is used in some parenteral protein products, but compatibility with filgrastim must be proven by forced degradation and particle counts rather than assumed from small-molecule multi-dose formulations. In-use particulate thresholds after repeated needle puncture are assessed by USP <787>; the number of approved punctures is established by the manufacturer’s in-use stability protocol under Ph. Eur. 5.1.3 and USP <51>. Chlorobutyl stoppers with fluoropolymer coating are selected to minimise leachable migration into the protein solution; vulcanised stoppers without coating release zinc and sulfur compounds that can accelerate aggregation. The vial is stored at 2–8°C; after first puncture, the product is typically discarded within 24 h for single-dose presentations. When a multi-dose configuration is evaluated, the cumulative room-temperature exposure must not exceed 48 h and the product is not frozen. Published data for preserved filgrastim multi-dose vials is limited; hence, this format requires biosimilar-specific validation and is uncommon in current commercial practice.